iv glutathione pubmed Efficacy of for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study Frontiers | Glutathione deficiency in

10.3390/jcm10020228 104 KochF.ThadenO.ConradS.TrndleK.FinkenzellerG.ZengerleR.et al (2022)

520 Imvax is conducting a randomized, multicenter, double-blind, placebo-controlled Phase IIb study (NCT04485949) to evaluate IGV-001 in patients with newly diagnosed GBM

This 1500mg research-grade preparation provides a substantial quantity for laboratory investigations into oxidative stress pathways, Phase II detoxification enzymes, and cellular redox homeostasis

National Institute of Alcohol Abuse and Alcoholism AA09526, Direccin General Poltica Cientfica y Tcnica, PM 950185, Plan Nacional de I+D grant SAF 970087-C01, SAF 97/0040, FIS 990568 and Europharma and SB-GETECCU